Limited access to necessary diagnostic tests in support of HIV/AIDS and associated co-infections, such as CD4 cell counts, viral load, tuberculosis microscopy or molecular diagnosis, drug susceptibility testing, and cryptococcal antigen testing among others, negatively contributes to the adequate clinical diagnosis, and consequently delays initiation of drug therapy in LMIC, particularly in sub-Saharan Africa [31,32]. The gene discussed is CD4; the disease is AIDS.